<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947609</url>
  </required_header>
  <id_info>
    <org_study_id>SEARCH TB Px</org_study_id>
    <nct_id>NCT00947609</nct_id>
  </id_info>
  <brief_title>Improving Latent Tuberculosis (TB) Diagnosis in Thai Children</brief_title>
  <acronym>TB Px</acronym>
  <official_title>Improving the Diagnosis and Management of Latent Tuberculosis in Thai Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South East Asia Research Collaboration with Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York Blood Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Sirikit National Institute of Child Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>South East Asia Research Collaboration with Hawaii</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective study to improve the diagnosis and management of latent TB in&#xD;
      HIV-infected and HIV uninfected children in Thailand. The objectives are to assess the&#xD;
      sensitivity and specificity of IGRAs (T-Spot®.TB, a T-cell-based assay, and QuantiFERON®-TB&#xD;
      Gold In-tube, a whole blood assay), TST, and a refined symptom-based questionnaire in&#xD;
      diagnosing latent TB in 166 HIV-infected and HIV uninfected children in Thailand, and to&#xD;
      evaluate the influence of age, nutritional and immune status on children's response to the&#xD;
      IGRAs. These children will be screened for TB with a detailed TB contact history,&#xD;
      symptom-based questionnaire, physical examination, TST, chest radiograph (and abdominal&#xD;
      ultrasound for those with abdominal symptoms), IGRAs, and clinical specimens for acid fast&#xD;
      bacilli stain and culture. A diagnostic algorithm will be generated using the combination of&#xD;
      test modalities with the highest sensitivity and specificity results.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives&#xD;
&#xD;
        -  To compare the utility of IGRAs, T-Spot®.TB and QuantiFERON®-TB Gold In-Tube, and TST&#xD;
           for screening of latent TB in HIV-infected children&#xD;
&#xD;
        -  To compare these different screening modalities in HIV-infected children to HIV&#xD;
           uninfected children&#xD;
&#xD;
        -  To assess the influence of age, nutritional and immune status, prior BCG and TST status&#xD;
           on children's response to IGRAs&#xD;
&#xD;
        -  To assess the prognostic value of IGRAs vs. TST in predicting development of active TB&#xD;
           in children over 9 months&#xD;
&#xD;
      Research questions:&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      What is the sensitivity and specificity of IGRAs and TST in screening for latent TB in&#xD;
      HIV-infected and HIV uninfected children in Thailand?&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
      How do age, nutritional and immune status, prior BCG and PPD status influence children's&#xD;
      response to IGRAs? What is the prognostic value of IGRAs vs. TST in predicting development of&#xD;
      active TB in children over 9 months?&#xD;
&#xD;
      This is a prospective cohort study conducted at two sites in Bangkok, Thailand: HIV&#xD;
      Netherlands Australia Thailand (HIV-NAT) Clinic/Chulalongkorn Hospital and Queen Sirikit&#xD;
      National Institute of Child Health.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">158</enrollment>
  <condition>Latent Tuberculosis</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>HIV-infected and HIV-uninfected children</arm_group_label>
    <description>HIV-infected and HIV uninfected children with recent exposure to adults with active tuberculosis will be referred to the two study sites (HIV-NAT/Chulalongkorn and Queen Sirikit) for eligibility screening and enrollment in the study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Thai children between the ages of 2 months and 16 years with exposure to active TB adult&#xD;
        cases will be referred to the two study sites for eligibility screening.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have close contact with a person &gt; 15 years of age who had active pulmonary (±&#xD;
             extrapulmonary), sputum AFB positive TB (household member or non-household member with&#xD;
             contact &gt; 120 hours/month) during the past year&#xD;
&#xD;
          2. Are between the ages of 2 months and 16 years&#xD;
&#xD;
          3. Parents or caregivers provide informed consent to participate&#xD;
&#xD;
          4. Provide child assent for children aged ≥ 7 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Child and/or parent/caregiver who refuse study participation&#xD;
&#xD;
          2. Are currently receiving antituberculosis medications for TB disease&#xD;
&#xD;
          3. Have recently been diagnosed with active TB within past 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jintanat Ananworanich, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South East Asia Research Collaboration with Hawaii, HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piyarat Suntarattiwong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Sirikit National Institute of Child Health, Bangkok, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon Tsiouris, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HIV Netherlands Australia Thailand (HIV-NAT) Research Organization</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Sirikit National Institute of Child Health</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>July 27, 2009</study_first_submitted>
  <study_first_submitted_qc>July 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2009</study_first_posted>
  <last_update_submitted>June 5, 2012</last_update_submitted>
  <last_update_submitted_qc>June 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Hong Van Tieu</investigator_full_name>
    <investigator_title>Co-investigator</investigator_title>
  </responsible_party>
  <keyword>Latent tuberculosis</keyword>
  <keyword>HIV</keyword>
  <keyword>Children</keyword>
  <keyword>Interferon gamma release assays</keyword>
  <keyword>Thailand</keyword>
  <keyword>QuantiFERON TB Gold In-tube</keyword>
  <keyword>T-Spot.TB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

